scispace - formally typeset
M

Magali Haas

Researcher at Johnson & Johnson Pharmaceutical Research and Development

Publications -  34
Citations -  1389

Magali Haas is an academic researcher from Johnson & Johnson Pharmaceutical Research and Development. The author has contributed to research in topics: Medicine & Population. The author has an hindex of 16, co-authored 28 publications receiving 1073 citations.

Papers
More filters
Journal ArticleDOI

International meta-analysis of PTSD genome-wide association studies identifies sex- and ancestry-specific genetic risk loci

Caroline M. Nievergelt, +213 more
TL;DR: A GWAS from the Psychiatric Genomics Consortium is reported in which two risk loci in European ancestry and one locus in African ancestry individuals are identified and it is found that PTSD is genetically correlated with several other psychiatric traits.
Journal ArticleDOI

Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study.

TL;DR: At daily doses of 0.5-2.5 mg and 3-6 mg, risperidone was effective and well tolerated in children and adolescents experiencing acute manic or mixed episodes of bipolar I disorder.
Journal ArticleDOI

A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia.

TL;DR: Risperidone 1-3 mg/day and 4-6mg/day were well tolerated and effective in adolescents experiencing acute episodes of schizophrenia, and the benefit-risk profile suggests that a dose of 1- 3 mg/ day might be optimal for this population.
Journal ArticleDOI

Management of psychiatric disorders in children and adolescents with atypical antipsychotics: a systematic review of published clinical trials.

TL;DR: The review of published scientific data suggests that most of the atypical antipsychotics, excluding clozapine, have a favourable risk/benefit profile and effectively reduce disabling behaviours in paediatric psychiatric patients.

tranSMART: An Open Source and Community-Driven Informatics and Data Sharing Platform for Clinical and Translational Research.

TL;DR: Significant transformative effects of tranSMART includes allowing for all its user community to benefit from experts globally, and capturing the best of innovation in analytic tools, a growing ‘big data’ resource, and convergent standards.